Analyst Price Targets — FDMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 9:08 pm | — | Goldman Sachs | $32.00 | $11.65 | TheFly | 4D Molecular price target lowered to $32 from $33 at Goldman Sachs |
| May 8, 2026 11:53 am | — | Goldman Sachs | $33.00 | $9.93 | TheFly | 4D Molecular price target lowered to $33 from $38 at Goldman Sachs |
| November 11, 2025 10:23 am | Gena Wang | Barclays | $33.00 | $10.17 | TheFly | 4D Molecular price target lowered to $33 from $38 at Barclays |
| October 31, 2025 1:20 pm | Mani Foroohar | Leerink Partners | $17.00 | $11.50 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners |
| October 21, 2025 1:11 pm | Lisa Walter | RBC Capital | $26.00 | $10.77 | StreetInsider | RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| January 11, 2025 7:38 pm | Judah Frommer | Morgan Stanley | $6.00 | $5.52 | TheFly | 4D Molecular price target lowered to $6 from $8 at Morgan Stanley |
| September 19, 2024 8:14 am | Kostas Biliouris | BMO Capital | $40.00 | $13.28 | StreetInsider | BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 8:06 am | Geulah Livshits | Loop Capital Markets | $39.00 | $13.31 | StreetInsider | Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 6:46 am | Matthew Caufield | H.C. Wainwright | $36.00 | $13.31 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| April 15, 2024 6:29 am | Lisa Walter | RBC Capital | $40.00 | $26.35 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital |
Latest News for FDMT
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor…
Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 17.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 974,173 shares of the company's stock after purchasing an additional 141,582 shares during the quarter.
Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 710,942 shares of the company's stock, valued at approximately $9,456,000. Deutsche Bank AG owned approximately 1.36% of 4D Molecular
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week high on Tuesday. The company traded as high as $15.03 and last traded at $14.55, with a volume of 3444983 shares. The stock had previously closed at $12.19. Wall Street Analyst Weigh In Several analysts have weighed in on
EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 11, 2026, the compensation committee of the Company's board of directors granted…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FDMT.
U.S. House Trading
No House trades found for FDMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.